TaGeza Biopharmaceuticals

Company Overview

Snapshot

Founded in February 2014 by Nadav Peles and Orit Harari-Steinberg, TaGeza Biopharmaceuticals operates with 1–10 employees. The company has secured funding across one round. In January 2019, the company received seed funding from aMoon Fund.

Business overview

TaGeza Biopharmaceuticals is a biotechnology startup focused on the study of cancer stem cells in aggressive forms of cancer. The company's core technology involves identifying central markers of highly aggressive cancer stem cells and developing drugs, specifically antibodies, to target them. This approach aims to eradicate various forms of treatment-resistant cancers. Operating in the Health Tech & Life Sciences sector, TaGeza serves the pharmaceutical and medical biotechnology industries, with a focus on drug discovery and development.

Company Intelligence Q&A

What is TaGeza Biopharmaceuticals' primary focus?

TaGeza Biopharmaceuticals is dedicated to the study of cancer stem cells in the deadliest forms of cancer, aiming to identify central markers and develop targeted drugs.

When was TaGeza Biopharmaceuticals founded?

TaGeza Biopharmaceuticals was founded in February 2014.

Who are the founders of TaGeza Biopharmaceuticals?

The company was co-founded by Nadav Peles and Orit Harari-Steinberg.

What is the company's current operational status?

TaGeza Biopharmaceuticals is currently non-active, having ceased to operate in September 2023.

What was a significant early milestone for TaGeza Biopharmaceuticals?

In February 2014, TaGeza Biopharmaceuticals began identifying markers of aggressive cancer stem cells and developing drugs, a key step in its pharmaceutical and diagnostics focus.